Cleave Biosciences Takes $42M Series A Round
This article was originally published in The Pink Sheet Daily
Four venture firms provided the lion's share of the money, which will support development of oncology drugs that affect protein homeostasis pathways.
You may also be interested in...
Asia Spotlight: Meet China’s New Innovators – Hua Medicine Looks To Take Flight With U.S. Venture Backing
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
FDA has expressed preference for having multiple confirmatory trials in the works to support an accelerated approval application.
Irish company will get a 24% stake in the U.S. biotech as part of an R&D collaboration centered around neurodegenerative diseases.